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Abstract
Background—Despite the good prognosis of pediatric mastocytosis, some patients suffer from
severe mast cell (MC) mediator-associated symptoms. The aim of this study was to identify
predictors for severe MC mediator release symptoms in children with mastocytosis in the skin
(MIS).
Methods—Serum baseline total tryptase (sbT) levels in 111 children with MIS – 80
maculopapular cutaneous mastocytosis/plaque mastocytosis, 22 nodular mastocytosis, and nine
diffuse cutaneous mastocytosis – were investigated as a predictive biomarker for the occurrence of
MC mediator-related signs and symptoms within the first 18 months after disease onset.
Results—Twelve children (11%) who showed extensive cutaneous disease involving >90% of
body surface area (BSA) suffered from severe symptoms requiring hospitalization, with (n = 5) or
without (n = 6) management in the intensive care unit (ICU) owing to life-threatening
complications. The median sbT was significantly (P < 0.001) higher in patients with extensive
cutaneous disease vs those with <90% of BSA involved (45.5 vs 5.2 µg/l, respectively), as well as
in children with grade 4 (severe mastocytosis-related symptoms requiring emergency therapy and
hospitalization) vs those with grade <4 (46.2 vs 5.2 µg/l, respectively). Receiver operating
characteristics curve analyses showed that the optimal cutoff s for sbT to predict the need for daily
antimediator therapy, hospitalization, and the management in an ICU were 6.6, 15.5, and 30.8 µg/
l, respectively (sensitivity and specificity of 77% and 79%, 100% and 95%, and 100% and 96%,
respectively).
Conclusions—Increased sbT in association with extensive cutaneous involvement identifies
patients at risk for severe MC activation events in pediatric mastocytosis.
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Currently, the World Health Organization (WHO) recognizes three major variants of
mastocytosis in the skin (MIS): maculopapular cutaneous mastocytosis (MPCM), diffuse
cutaneous mastocytosis (DCM), and solitary mastocytoma (1, 2). However, other variants of
MIS have also been reported, including plaque (PM), nodular (NM) and telangiectatic
cutaneous mastocytosis (3); in addition, criteria for the diagnosis of MIS have been
proposed (4).
It has been reported that serum baseline total tryptase (sbT) levels >20 µg/l in pediatric
cutaneous mastocytosis (CM) reflect either extensive skin involvement or the possibility of
systemic disease (5). Total tryptase levels include both mature and pro forms of tryptase;
protryptase is spontaneously and continuously secreted by unstimulated mast cells (MC),
while mature tryptase is stored in secretory granules until MC are activated to degranulate.
Nevertheless, the true significance of increased sbT levels at onset of pediatric mastocytosis
remains unclear. Although it has been proven that serum mature tryptase (smT) levels
transiently increase in most subjects with severe systemic anaphylaxis in association with
hypotension (6) and that detectable smT levels with a total tryptase/mature tryptase ratio ≤10
reflect systemic anaphylaxis (7), the exact percentage of patients at risk for severe MC
mediator-related symptoms remains unknown.
Here, we investigated the potential association between clinical and laboratory data and the
development of MC-related symptoms in a series of 111 children with mastocytosis, within
the first 18 months after disease onset. Overall, our results support a direct relationship
between sbT levels and the extent of skin involvement in pediatric mastocytosis and a
potential role for sbT levels at diagnosis in predicting the clinical severity in our population.
Methods
Patients
A total of 111 children – 58 boys (52%) and 53 girls (48%) – with a median age of 9 months
(range, 1 month–10 years) diagnosed with MIS on the basis of skin biopsy findings
according to consensus criteria (4) and referred (within the first 18 months from disease
onset) to the Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast, Toledo,
Spain) between January 2001 and December 2008 were studied. Because of the localized
nature of the disease and because systemic MC mediator-related symptoms are usually
absent, solitary mastocytoma cases were excluded from the study. The study was approved
by the local ethics committee, and only those patients for whom their parents gave an
informed consent to participate were enrolled in the study.
Patients were classified according to the type of skin lesions following consensus criteria
and the WHO classification (2, 4, 8) further modified by Hartmann and Henz (3). Extensive
skin disease was defined as MIS involving >90% of the body surface area (BSA) evaluated
as previously described (9). Mastocytosis-related symptoms together with data on specific
triggering factors were recorded. Severity was graded according to standard consensus
recommendations (4): grade 0 (no symptoms), grade 1 (mild, no therapy required), grade 2
(moderate, kept under control with antimediator-type drugs), grade 3 (severe, not
sufficiently controlled with therapy) and grade 4 (severe adverse events that require
emergency therapy and hospitalization); in this latter group, the frequency of severe adverse
events, total days of hospitalization, and the need for management at an intensive care unit
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(ICU) with vasoactive drugs, orotracheal intubation or blood transfusion support owing to
mastocytosis-related life-threatening adverse events were also recorded. According to these
criteria, several simplified categories of disease severity are considered for comparison
purposes, including grade 4 (hospitalization required) vs grade ≤3 (hospitalization not
required), and, among this latter group, grade ≤1 (no therapy required) vs grade ≥2
(antimediator therapy required).
Serum mast cell tryptase levels
SbT levels (CAP; Phadia Diagnostics, Uppsala, Sweden) were measured in all patients at the
time of referral. Additionally, smT levels were measured in eight cases by ELISA
(sensitivity of 1 ng/ml) as described elsewhere (10); in these patients, both serum total and
mature tryptase assays were performed in parallel at Virginia Commonwealth University
(Richmond, VA, USA).
Bone marrow studies
Bone marrow (BM) aspirate studies were performed in only three patients at the ICU under
general anesthesia and after premedication with H1 and H2 antihistamines. BM smears were
stained and analyzed as previously defined (11), and immunophenotypical analysis of BM
MC was performed according to the Spanish Network on Mastocytosis (REMA) consensus
procedures (12). Detection of somatic activating codon Asp816→Val KIT mutation was
performed on genomic DNA, as described elsewhere (13, 14).
Management of patients
Patients were managed according to well-defined guidelines (15–17) that included (i) careful
counseling of their parents and close communication with their pediatricians; (ii) strict
avoidance of factors triggering acute MC mediator release; and (iii) usage of protocols for
specific situations (e.g., fever, vaccination, teething, and anesthetic procedures).
Treatment consisted of different combinations of drugs, depending on the type and
frequency of the symptoms. In all cases with cutaneous symptoms, 0.21% water-soluble
topical sodium cromolyn (18) was used on demand. In patients with grade 1–2 disease,
cutaneous symptoms were treated with H1 antihistamines. For gastric symptoms, H2
antihistamines were employed, and for abdominal cramping and/or diarrhea, oral disodium
cromoglycate was added. Patients with grade ≥3 disease received daily oral disodium
cromoglycate and both nonsedating H1 and H2 antihistamines, as standard therapy. Sedating
H1 antihistamines, oral glucocorticosteroids, leukotriene antagonists, epinephrine or
benzodiazepines, among other drugs, were added when clinically indicated. Moreover, 1 :
1000 zinc sulfate wet-wrap therapy was used for severe cutaneous symptoms with blistering,
particularly in DCM patients, in association with daily topical sodium cromolyn and
continuous systemic therapy.
Statistical analyses
The Mann-Whitney U and the chi-square tests were used to assess the statistical significance
(P-value ≤0.05) of differences observed between groups for continuous nonparametric and
categorical variables, respectively. To identify optimal tryptase cutoff values for highest
sensitivity and specificity, receiver operating characteristics (ROC) curve analyses were
performed (19). ROC curves plotting sensitivity against 1-specificity were generated and the
areas under the curve (AUC) were calculated, in order to measure the accuracy of the test.
All statistical analyses were performed with SPSS 15.0 (SPSS, Chicago, IL, USA) and
MEDCALC (version 11.4; Medcalc, Mariakerke, Belgium).
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Results
Clinical findings
Overall, the median time from disease onset to referral was of 5 months (range, 6 days–17
months). Skin lesions were reported at birth in 17 patients (15%), while median age at
disease onset in the remaining 94 patients was of 3 months (range, 1 day–8 years). The
different subtypes of MIS observed included MPCM in 76/111 (68%), NM in 22/111 (20%),
DCM in 9/111 (8%), and PM in 4/111 (4%) cases. Additionally, Table 1 shows the
distribution of the subtypes of cutaneous involvement among the three different categories
of the disease (e.g., the checkpoint MIS and the two final diagnoses after BM study, CM,
and SM, defined according to consensus criteria). For further comparisons, PM patients
were included into the MPCM group, because most of them simultaneously presented
plaque and maculopapular skin lesions, and the plaques themselves usually derived from
large macules or by the confluence of small patches. Thirteen cases (12%; all nine DCM,
one NM, and three MPCM patients) had extensive cutaneous disease involving >90% of
BSA. Mutational studies were performed in skin biopsy samples in 19/111 cases (17%) and
the D816V KIT mutation was detected in three of them.
Skin rubbing, heat, and hot bath or shower were the most common triggers for MC-related
symptoms (Table 2). Other clinically relevant triggers were irritability, fever, and teething,
whereas drugs, food, and vaccination were rarely involved (except among DCM patients)
(Table 2). The most frequent symptoms were pruritus (79%), blistering (55%), flushing
(46%), diarrhea (21%), and abdominal cramping (17%). Twelve children (11%) – all nine
DCM patients, one NM, and two MPCM – had grade 4 disease requiring hospitalization to
control severe adverse events (Table 3) – median hospitalization time of 16 days (range, 3–
200 days) – in association with both extensive cutaneous disease and acute recurrent
episodes consisting of pruritus, generalized blistering, and flushing, usually associated with
abdominal cramping and/or diarrhea. ICU admission was required in five of these 12
patients (42%), because of life-threatening adverse events during acute episodes, including
upper gastrointestinal bleeding (GIB) in the absence of coagulopathy (n = 4), three of them
requiring blood transfusion, sepsis secondary to severe cutaneous infections (n = 3) caused
by Enterobacter cloacae, Staphylococcus epidermidis and Staphylococcus aureus,
respectively, and/or hypotension requiring epinephrine (n = 4). Noteworthily, in these latter
cases, hypotensive episodes were not directly related to sepsis or hypovolemia caused by
GIB, but to massive MC mediator release triggered by heat, rubbing, and fever in all cases.
Interestingly, sustained hypertension alternating with hypotensive episodes was observed in
one patient suffering from extensive MPCM who underwent chronic antihypertensive drug
therapy, but with periods when therapy was held owing to hypotensive episodes requiring
treatment with epinephrine. Once antihypertensive therapy was discontinued after 2 years of
treatment, blood pressure remained at normal levels for six additional years. Only two
patients required orotracheal intubation to achieve an adequate sedation; nevertheless, none
of the patients showed respiratory distress, cyanosis, or neurological symptoms, including
seizures.
Serum tryptase levels
The median sbT level for the whole group was 6 µg/l (range, 1–213 µg/l). A significantly
higher (P < 0.001) median sbT level was found in cases with extensive cutaneous
involvement vs those without (46 vs 5.2 µg/l; range, 16–213 vs 1–30 µg/l, respectively). In
line with these findings, the median sbT level was significantly higher (P < 0.001) among
DCM (45.5 µg/l; range, 24–213 µg/l) vs both MPCM (5.1 µg/l; range, 1–79 µg/l) and NM
(8.1 µg/l; range, 2.8–183 µg/l) cases, and among NM vs MPCM patients (P = 0.02; Fig. 1A);
such differences were retained even when cases with extensive disease (three MPCM
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patients and one NM child) were excluded from the analysis: median of 7.9 µg/l (range, 2.8–
29 µg/l) in NM vs 5.1 µg/l (range, 1–30 µg/l) in MPCM cases (P = 0.01). In line with these
observations, sbT levels >11.4 µg/l and >20 µg/l were detected in all DCM cases but in only
a small proportion of NM (23% and 9%, respectively) and MPCM (9% and 5%,
respectively) patients. Regarding severity of MC mediator release symptoms, the median
sbT level was significantly (P < 0.001) higher among patients with grade 4 disease than all
other children (46 vs 5.2 µg/l; range, 16–213 vs1–30 µg/l, respectively; Fig. 1B). Similar
results were observed between these groups after excluding grade 4 disease patients who
required to be treated in the ICU. Accordingly, a sbT >20 µg/l was detected in 11/12 (92%)
patients with grade 4 disease vs 4/99 (4%) with grade ≤3 disease (P < 0.001). Among
patients with grade ≤3 disease (n = 99), the median sbT level was significantly (P < 0.001)
higher in patients with grade ≥2 than in those with grade ≤1 disease (8.1 vs 4.8 µg/l; range,
1.3–30.2 vs 1–28.5 µg/l, respectively). ROC curve analyses (Fig. 2) showed that the most
efficient cutoff values for a sbT level to predict grade ≥2 disease, grade 4, and the need for
management in an ICU were 6.6, 16, and 31 µg/l, respectively; at these cutoff levels, an
AUC of 0.80 (P < 0.001), 0.99 (P < 0.001), and 0.98 (P < 0.001) was observed with a
sensitivity/specificity of 77%/79%, 100%/95%, and 100%/96%, respectively. Importantly,
no significant differences (P > 0.05) were observed according to time from disease onset to
referral, among the different groups of patients defined by disease severity. Additionally,
measurable smT levels during acute clinical episodes were detected in 7/15 studied acute
events occurring in four subjects, the highest smT values corresponding to hypotensive
episodes that required treatment with epinephrine in two cases (patients #7 and # 10) (Table
4).
Screening for systemic mastocytosis
BM aspirate samples were obtained in 3/5 children with extensive skin involvement by
mastocytosis affecting >90% of BSA and increased sbT, who were admitted to the ICU for
emergency treatment because of near-fatal MC-related symptoms (patients #7, #10, and #17
in Table 4). According to BM findings, systemic mastocytosis (SM) was ruled out in a DCM
case with a sbT of 69 µg/l (patient #17); conversely, it was confirmed in the other two
patients. One of these two latter cases showed spindle-shaped, CD25+ BM MC carrying the
D816V KIT mutation in association with MPCM and sbT of 79 µg/l (patient #10) and he
was classified as indolent SM (ISM); the other patient displayed marked BM infiltration
with large aggregates of round, well-granulated CD25-negative MC lacking the D816V KIT
mutation, consistent with the diagnosis of well-differentiated SM (WDSM) (20–23) in
association with NM and sbT of 183 µg/l (patient #7).
Discussion
Here, we show that in our cohort of pediatric mastocytosis, sbT levels are associated with
the extent of skin involvement and the clinical severity of the disease at presentation; in fact,
sbT levels identified patients at risk for suffering severe, even life-threatening MC activation
events, as well as those who were more likely to have only mild to moderate symptoms.
These findings support future usage of sbT to prospectively develop and efficiently adopt
preventive measures in individual patients, including early intensive antimediator therapy.
Here, we confirm previous observations showing that skin rubbing and hot temperatures
(24) are the most frequent triggers of MC mediator release symptoms. Interestingly,
irritability defined as a hostile behavior characterized by fussing, whining, impatience,
anger, and violent rage was found to be a relatively frequent trigger of symptoms in our
series, particularly among patients with DCM. Irritability in children is often equated to
anxiety in adults, which is known to release neuropeptides from local nerve endings such as
corticotropin-releasing hormone, substance P, and neurotensin, leading to MC activation and
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increased vascular permeability (25–27). Additionally, detailed analysis of our cases showed
that extensive cutaneous disease is not restricted to DCM cases, but it is also found in a
small subset of NM and MPCM patients. In a retrospective study including 19 pediatric
mastocytosis patients, no correlation was found between cutaneous involvement and disease
symptoms (9). Conversely, our results indicate that symptoms at disease onset are more
severe among DCM vs other MIS groups. Furthermore, although grade 4 disease was most
commonly found among DCM, it was also seen in NM and MPCM cases, particularly when
skin lesions involved >90% BSA. Moreover, life-threatening episodes, secondary to massive
MC mediator release requiring treatment at an ICU, were invariably associated with
extensive cutaneous involvement.
Interestingly, hypertension alternating with hypotensive reactions was detected in one
patient suffering from extensive MPCM, in whom systemic involvement was confirmed
after BM analysis. In line with this observation, it has been reported that chymase (28)
converts angiotensin I to the vasoconstrictive peptide angiotensin II, and big endothelins to
vasoconstrictive endothelins (e.g., endothelin-1) (29). Thus, because other potential
secondary causes for hypertension were excluded, this MC protease could be involved in the
genesis of hypertension in this child.
It is well known that patients with extensive cutaneous mastocytosis lesions may have
elevated sbT levels (5, 30); however, in a series of 19 pediatric mastocytosis cases, sbT
levels did not significantly correlate with the extent of skin involvement, but instead, they
were only increased in children who had systemic disease (9). In our series, the highest sbT
values corresponded to patients with extensive skin involvement and to those expected to
have the most severe anaphylactic reactions. Overall, sbT levels >16 and >31 µg/l were
associated with grade 4 disease requiring hospitalization and need to be treated at an ICU,
respectively. Notably, nearly all children with grade 4 disease had been referred to the
CLMast after hospitalization because of severe adverse events. In our series, all but one of
these grade 4 disease patients showed dramatic improvement in their MC mediator
symptoms after starting antimediator therapy (data not shown). Consequently, early
intensive antimediator therapy should probably be given as soon as possible to children
identified to be at risk for severe mastocytosis-related anaphylaxis on the basis of the extent
of cutaneous involvement and a sbT >16 µg/l. In the only nonresponding case,
corresponding to the patient with WDSM, cytoreductive therapy with hydroxyurea was
added based on a good response achieved in an adult with progressing WDSM (Escribano L,
personal observation) and the safety profile of hydroxyurea in children with sickle cell
anemia (31–33). Interestingly, a dramatic response was obtained in this patient with a
progressive decrease in clinical symptoms, skin lesions, and the need for intensive
antimediator therapy. Careful prospective studies of a large series of patients will reveal the
true role of sbT level monitoring and the subtype and extent of MIS in predicting long-term
clinical outcome.
Interestingly, BM studies performed in three grade 4 patients who systematically showed
>90% BSA involvement and sbT >20 µg/l confirmed the presence of ISM and WDSM (20,
21) in two cases, but normal BM findings in the third one. Despite these observations, the
actual frequency of systemic involvement in children with MIS cannot be accurately
established, because the prediagnostic MIS checkpoint may turn out to be SM upon an
eventual BM study performed, when indicated, at an older age. Likewise, whether patients
with extensive cutaneous disease in association with systemic involvement are likely to
suffer from more severe symptoms than those with extensive disease restricted to skin, while
expected, remains unknown. On the other hand, a progressive decrease in sbT over time, in
parallel with clinical improvement, was observed in most cases with increased sbT at
referral (data not shown). Potential explanations for such decreasing sbT levels in children
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include a decrease in the total MC burden to body mass ratio with age, a decrease in the
amount of tryptase per MC that is being spontaneously secreted, decreased MC mediator
releasability owing to hormonal changes or antimediator therapy, and a decrease in the total
body burden of MC as a consequence of the natural course of the disease. Altogether, these
findings suggest that in pediatric mastocytosis, sbT could reflect both the risk of MC
activation events and the MC burden, each of which may decline over time. Interestingly, an
acute but transient increase in smT levels was detected during severe hypotension episodes
in some patients with grade 4 disease, becoming undetectable outside of these acute
episodes; these findings are consistent with a release of mature tryptase by degranulation of
activated MC. In addition, they support the notion that MC undergo massive degranulation
(6) during acute episodes and suggest a potential utility of smT levels to confirm acute
anaphylaxis owing to MC mediator release. By contrast, in other cases, elevation in sbT in
the absence of a detectable rise in smT was observed, as also described in mild systemic
allergic reactions (in the absence of hypotension) observed after experimental insect sting
challenges (34, 35) and rush immunotherapy (36). A potential explanation for such apparent
discrepancy could be that in such cases, symptoms might result from the activation of small
numbers of MC in a specific tissue environment, which produces an insufficient amount of
mature tryptase to affect systemic tryptase levels in blood. However, despite treatment with
antimediator therapy, sbT levels remained high in the patients here analyzed, consistent with
the notion that such increased sbT levels primarily reflect high protryptase levels because
protryptases are secreted continuously by unstimulated MC.
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Figure 1.
Serum baseline total tryptase (sbT) levels detected at patient referral among the different
subtypes of mastocytosis in the skin (MIS) (panel A) and among the different groups of MIS
established according to the clinical severity of anaphylaxis (panel B). Higher baseline sbT
levels were detected in panel A, DCM vs both NM (P < 0.001) and MPCM (P < 0.001), NM
vs MPCM (P = 0.02); panel B, grade 4 patients vs all the other groups (P < 0.001).
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Figure 2.
Receiver operating characteristics (ROC) curves searching for the utility of sbT levels for
the identification of patients with grade ≥2 (panel A), grade 4 (panel B) disease and those
who needed to be treated in an intensive care unit (panel C). The optimal sbT cutoff values
detected in each case were of 6.6 µg/l (panel A), 16 µg/l (panel B), and 31 µg/l (panel C).
AUC, area under the curve; CI, confidence interval.
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Table 1
Distribution of the different patterns of cutaneous involvement in MIS, CM and SM patients.
MIS* (n=12) CM* (n=97) SM* (n=2)
MPCM/PM 3 (25) 76 (78) 0 (0)
NM 1 (8) 20 (21) 1 (50)
DCM 8 (67) 1 (1) 1 (50)
Results expressed as number of cases (%).
MIS, mastocytosis in the skin; CM, cutaneous mastocytosis; SM, systemic mastocytosis; MPCM, maculopapular cutaneous mastocytosis; PM,
plaque mastocytosis; NM, nodular mastocytosis; DCM, diffuse cutaneous mastocytosis.
*According to standardized consensus recommendations (4): MIS is a pre-diagnostic checkpoint corresponding to patients who have serum
tryptase levels between 20 and 100 µg/L in the absence of a BM study; CM include patients with serum tryptase levels <20 µg/L and those with
proven absence of BM infiltration; SM corresponds to patients with proven BM infiltration.
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Table 2
Clinical characteristics of patients (n=111) distributed according to the specific subvariants of mastocytosis in
the skin.
MPCM/PM (n=80) NM (n=22) DCM (n=9) p value
Demographics
 Male 39 (49) 15 (68) 4 (44) NS
 Age* at onset1 3 (0–106) 2 (0–9) 3 (0–8) NS
 Age* at referral1 11 (1–114) 6 (1–23) 6 (3–25) NS
 Time* from onset to referral1 7 (0–17) 4 (0–15) 5 (0–16) NS
Areas of skin involved
 Trunk 76 (95) 22 (100) 9 (100) NS
 P/D extremities 62 (77) / 29 (36) 21 (95)/ 11 (50) 9 (100)/9 (100) NS/.04
 Neck 45 (56) 16 (73) 9 (100) .02
 Scalp 31 (39) 13 (59) 9 (100) .001
Extension of cutaneous disease
 >90%of BSA 3 (4) 1 (4) 9 (100) <.001
Type of MC-related symptoms
 Blistering 35 (44) 17 (77) 9 (100) .003
 Pruritus 59 (74) 20 (91) 9 (100) NS
 Flushing 30 (37) 12 (54) 9 (100) .001
 Abdominal cramping 14 (17) 1 (4) 4 (44) .04
 Diarrhea 12 (15) 6 (27) 5 (56) .01
 Hypotension 1 (1) 1 (4) 2 (22) .03
 GIB 1 (1) 1 (4) 2 (22) .03
Grading of symptoms†
 Grade 0 21 (26) 2 (9) 0 (0) NS
 Grade 1 35 (44) 10 (45) 0 (0) .007
 Grade 2 19 (24) 7 (32) 0 (0) NS
 Grade 3 3 (4) 2 (9) 0 (0) NS
 Grade 4 2 (2) 1 (4) 9 (100) <.001
Triggers for symptoms
 Skin friction 47 (59) 18 (82) 9 (100) .02
 Heat and/or hot water 46 (57) 19 (86) 9 (100) .02
 Cold 5 (6) 2 (9) 2 (22) NS
 Exercise 2 (2) 1 (4) 0 (0) NS
 Food‡ 4 (5) 1 (4) 1 (11) NS
 Drugs§ 3 (4) 0 (0) 1 (11) NS
 Vaccines 3 (4) 2 (9) 4 (44) .002
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MPCM/PM (n=80) NM (n=22) DCM (n=9) p value
 Irritability 21 (26) 6 (27) 4 (44) NS
 Teething 12 (15) 8 (36) 3 (33) NS
 Fever 16 (20) 7 (32) 8 (89) <.001
Results expressed as number ot cases (%) and as1 median (range). P value reters to compansions between DCM and all the other cases.
MC, mast cell; MPCM, maculopapular cutaneous mastocytosis; PM, plaque mastocytosis; NM, nodular mastocytosis; DCM, diffuse cutaneous
mastocytosis; P, proximal; D, distal; BSA, body surface area; GIB, gastrointestinal bleeding; NS, non-significant.
*
Expressed in months.
†According to standardized consensus recommendations (reference #4): grade 0 (no symptoms), grade 1 (mild, no therapy required), grade 2
(moderate, kept uder control with antimediator-type drugs), grade 3 (severe, not sufficiently controlled with therapy) and grade 4 (severe adverse
event, requires emergency therapy and hospitalization).
‡Culprit foods (and the corresponding symptoms) included prawn (angioedema), banana (pruritus), kiwi and tomato (pruritus), pig ribs (hives and
pruritus), bread roll (pruritus) and chocolate, egg and lentil (hives, flushing, blistering and diarrhea). No specific IgE against the involved foods
were detected in any case.
§Culprit drugs (and the corresponding symptoms) included dipyrone and diclofenac (hives, pruritus and angioedema), ibuprofen (hives),
polivitaminic complex (pruritus) and ibuprofen (hives and angioedema).
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